A Randomized, Blinded, Placebo-Controlled Dose-Ranging Phase 1b Study of the Safety, Pharmacokinetics, and Antiviral Activity of ABI-4334 in Subjects with Chronic Hepatitis B Virus Infection
ABI-4334-102
Phase 1 other active
Quick answer
A Randomized, Blinded, Placebo-Controlled Dose-Ranging Phase 1b Study of the Safety, Pharmacokinetics, and Antiviral Activity of ABI-4334 in Subjects with Chronic Hepatitis B Virus Infection for chronic hepatitis B virus infection (cHBV) is a Phase 1 program (other) at ASSEMBLY BIOSCIENCES, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- ASSEMBLY BIOSCIENCES, INC.
- Indication
- chronic hepatitis B virus infection (cHBV)
- Phase
- Phase 1
- Modality
- other
- Status
- active